ABSTRACT
Within the context of the standard SIR model of pandemics, we show that the asymmetry in the peak in recorded daily cases during a pandemic can be used to infer the pandemic R-parameter. Using only daily data for symptomatic, confirmed cases, we derive a universal scaling curve that yields: (i) reff, the pandemic R-parameter; (ii) Leff, the effective latency, the average number of days an infected individual is able to infect others and (iii) α, the probability of infection per contact between infected and susceptible individuals. We validate our method using an example and then apply it to estimate these parameters for the first phase of the SARS-Cov-2/Covid-19 pandemic for several countries where there was a well separated peak in identified infected daily cases. The extension of the SIR model developed in this paper differentiates itself from earlier studies in that it provides a simple method to make an a-posteriori estimate of several useful epidemiological parameters, using only data on confirmed, identified cases. Our results are general and can be applied to any pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
GB was partly supported by grants from DoD (KC180159) and NIH (P01CA250957). GB thanks Professor Charles DeLisi for many discussions and collaboration on earlier (unpublished) work on the SARS-CoV-2 pandemic using the SIR model. GB also thanks the Aspen Center for Physics, which is supported by National Science Foundation grant PHY-1607611, the Geballe Lab for Advanced Materials at Stanford University, and Professor Gautam Mandal and the Tata Institute of Fundamental Research for their kind hospitality while this work was being done.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
https://covid19.who.int/WHO-COVID-19-global-data.csv. https://www.ecdc.europa.eu/en/publications-data/covid-19-testing
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Earlier version was unreadable. Results unchanged.
Data Availability
All data produced in the present work are contained in the manuscript and supplementary material.
